ArticleCureus2025
Identification of Key Genes in Diabetic Retinopathy Using Bioinformatics and Machine Learning Approaches.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aimed to identify key genes associated with diabetic retinopathy (DR) by applying bioinformatics and machine learning techniques to publicly available transcriptomic datasets. We further evaluated their diagnostic performance and explored their potential biological functions and upstream regulatory mechanisms, providing a theoretical basis for the early diagnosis and molecular-targeted therapy of DR. Methods DR-related transcriptomic datasets GSE94019 and GSE60436 were obtained from the Gene Expression Omnibus (GEO) database, with GSE94019 serving as the training set and GSE60436 as the validation set. The data were then subjected to normalization and differential expression analysis. Feature genes were selected using the Least Absolute Shrinkage and Selection Operator (LASSO) regression and Support Vector Machine-Recursive Feature Elimination (SVM-RFE) algorithms. Overlapping genes were identified as key candidates. Diagnostic performance was evaluated by plotting receiver operating characteristic (ROC) curves using the R package pROC. Functional enrichment analysis, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, was performed on differentially expressed genes (DEGs) associated with the key gene. Potential upstream miRNAs and lncRNAs were predicted using the miRanda, miRDB, TargetScan, and spongeScan databases, and a lncRNA-miRNA-mRNA regulatory network was constructed. Results A total of 790 DEGs were identified, including 370 upregulated and 419 downregulated genes. Cross-validation using LASSO and SVM-RFE identified Collagen Type VI Alpha 2 Chain (COL6A2) and LINC01247 as key genes. COL6A2 was significantly upregulated in the DR group. ROC analysis revealed high diagnostic accuracy, with area under the curve (AUC) values of 1.00 (training set) and 0.89 (validation set). In contrast, LINC01247 was significantly downregulated, but its AUC values were 1.00 (training set) and 0.52 (validation set), indicating limited diagnostic value; thus, it was excluded from further analysis. Functional enrichment centered on COL6A2 suggested that its associated DEGs were involved in aberrant extracellular matrix (ECM) organization, cell adhesion, angiogenesis, and inflammatory responses. Moreover, regulatory network analysis indicated that hsa-miR-762 and hsa-miR-29a-3p may indirectly regulate COL6A2 expression by competitively binding multiple lncRNAs (e.g., PABPC1L2B-AS1 and RP11-223P11.3), forming a potential ceRNA regulatory axis. Conclusion This study identifies COL6A2 as a key gene in DR, characterized by significant upregulation in DR tissues and close involvement in ECM remodeling, cell adhesion, and angiogenesis. These findings provide novel molecular targets and theoretical insights for elucidating the molecular mechanisms of DR and for improving early diagnostic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.